DVA trades 28.7% below Wall Street's consensus target of $235.67.
Last 12 months price action with 12-month analyst target path
The base valuation assumes DVA achieves its forward estimates and maintains a stable P/E multiple of 12.3x. This scenario reflects the blended consensus of 23 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of September 24, 2026, DaVita Inc. (DVA) has a Wall Street consensus price target of $235.67, based on estimates from 23 covering analysts. With the stock currently trading at $183.14, this represents a potential upside of +28.7%. The company has a market capitalization of $11.76B.
Analyst price targets range from a low of $215.00 to a high of $270.00, representing a 23% spread in expectations. The median target of $222.00 differs from the mean, suggesting potential outlier estimates. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Hold, with 10 analysts rating the stock as a Buy or Strong Buy,12 rating it Hold, and 1 rating it Sell or Strong Sell. The mixed ratings reflect uncertainty about near-term direction.
From a valuation perspective, DVA trades at a trailing P/E of 19.3x and forward P/E of 12.3x. The forward PEG ratio of 1.49 indicates reasonable valuation for growth. Analysts expect EPS to grow +15.8% over the next year.
Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $311.66, with bear and bull scenarios of $196.35 and $410.64 respectively. Model confidence stands at 48/100, suggesting limited visibility into future performance.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 FMSFresenius Medical Care AG & Co. KGaA | $12.0B | $22.41 | $23.57 | +5.2% | Hold | 10.9x | 21 |
 FXNCFirst National Corporation | $266M | $29.40 | $21.00 | -28.6% | Buy | 12.1x | 1 |
 UNHUnitedHealth Group Incorporated | $337.2B | $371.29 | $473.89 | +27.6% | Buy | 18.7x | 52 |
 HUMHumana Inc. | $45.0B | $374.80 | $418.53 | +11.7% | Hold | 40.9x | 44 |
 CNCCentene Corp. | $30.7B | $62.07 | $68.29 | +10.0% | Buy | 12.7x | 44 |
 USPHU.S. Physical Therapy, Inc. | $1.3B | $82.65 | $90.00 | +8.9% | Buy | 30.0x | 13 |
 AMSFAMERISAFE, Inc. | $456M | $24.37 | $32.00 | +31.3% | Buy | 12.3x | 6 |
 PNTGThe Pennant Group, Inc. | $1.4B | $39.65 | $44.50 | +12.2% | Buy | 28.4x | 7 |
 ADUSAddus HomeCare Corporation | $2.1B | $114.93 | $118.33 | +3.0% | Buy | 16.3x | 16 |
 BAXBaxter International Inc. | $12.1B | $23.49 | $25.00 | +6.4% | Hold | 11.4x | 36 |
Quick answers to the most common questions about buying DVA stock.
The consensus Wall Street price target for DVA is $235.67, representing 28.7% upside from the current price of $183.14. With 23 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
DVA has a consensus rating of "Hold" based on 23 Wall Street analysts. The rating breakdown is mixed, with 12 Hold ratings making up the largest segment. The consensus 12-month price target of $235.67 implies 28.7% upside from current levels.
With a forward P/E of 12.3366x, DVA trades at a relatively low valuation. The consensus target of $235.67 implies 28.7% appreciation, suggesting meaningful undervaluation.
The most bullish Wall Street analyst has a price target of $270 for DVA, while the most conservative target is $215. The consensus of $235.67 represents the median expectation. Our quantitative valuation model projects a bull case target of $411 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.
DVA is well covered by analysts, with 23 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 10 have Buy ratings, 12 recommend Hold, and 1 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month DVA stock forecast based on 23 Wall Street analysts shows a consensus price target of $235.67, with estimates ranging from $215 (bear case) to $270 (bull case). The median consensus rating is "Hold". Our proprietary valuation model produces a base case fair value of $312, with bear/bull scenarios of $196/$411.
Our quantitative valuation model calculates DVA's fair value at $312 (base case), with a bear case of $196 and bull case of $411. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 48/100.
DVA trades at a forward P/E ratio of 12.3x based on next-twelve-months earnings estimates compared to a trailing P/E of 19.3x. The lower forward P/E indicates analysts expect earnings growth. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Wall Street analysts are very optimistic on DVA, with a "Hold" consensus rating and $235.67 price target (28.7% upside). 10 of 23 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
DVA analyst price targets range from $215 to $270, a 23% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $235.67 consensus represents the middle ground. Our model's $196-$411 range provides an independent fundamental perspective.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.